Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2026 08:05 ET | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Sangamo has now submitted the ST-920 preclinical and clinical modules to the FDA for review.
November 21, 2025 08:05 ET | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

U.S. FDA has accepted Sangamo’s request for a rolling submission and review of the BLA for ST-920 in Fabry disease